Abdominal Obesity Linked to All-Cause Mortality in HFpEF

Share this content:
Abdominal Obesity Linked to All-Cause Mortality in HFpEF
Abdominal Obesity Linked to All-Cause Mortality in HFpEF

MONDAY, Nov. 27, 2017 (HealthDay News) -- For patients with heart failure with preserved ejection fraction (HFpEF), abdominal obesity is associated with increased risk of all-cause mortality, according to a study published in the Dec. 5 issue of the Journal of the American College of Cardiology.

Tetsuro Tsujimoto, M.D., Ph.D., and Hiroshi Kajio, M.D., Ph.D., from the National Center for Global Health and Medicine in Tokyo, and colleagues examined the correlation between abdominal obesity and the risk of all-cause mortality using data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Data were included for 3,310 patients with HFpEF: 2,413 with abdominal obesity and 897 patients without abdominal obesity.

The researchers found that 500 patients died during a mean follow-up of 3.4 years. For patients with and without abdominal obesity, all-cause mortality rates were 46.1 and 40.7 events per 1,000 person-years, respectively. The risk of all-cause mortality was significantly higher for patients with versus those without abdominal obesity, after multivariable adjustment (adjusted hazard ratio, 1.52). Patients with versus without abdominal obesity also had significantly higher risk of cardiovascular and non-cardiovascular mortality (adjusted hazard ratios, 1.50 and 1.58, respectively).

"The risk of all-cause mortality was significantly higher in patients with HFpEF with abdominal obesity than in those without abdominal obesity," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »